Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
- Associated Therapies
- -
A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1228
- Registration Number
- NCT00090753
Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-06-24
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 150
- Registration Number
- NCT00086086
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-04-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 324
- Registration Number
- NCT00081471
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 313
- Registration Number
- NCT00077766
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00070382
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Heart Failure and Anemia
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-11-19
- Last Posted Date
- 2009-08-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 300
- Registration Number
- NCT00049985
Anemia in Patients With a Non-Myeloid Malignancy
- First Posted Date
- 2002-05-29
- Last Posted Date
- 2008-09-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 707
- Registration Number
- NCT00038064
Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-05-08
- Last Posted Date
- 2009-05-11
- Lead Sponsor
- Amgen
- Registration Number
- NCT00036023
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath